Systemic administration of the nitric oxide (NO) synthase inhibitor Nomega-nitro--arginine methyl ester (L-NAME) to rabbits bearing a corneal implant blocked vascular endothelial growth factor (VEGF), but not basic fibroblast growth factor (bFGF)-induced angiogenesis. L-NAME completely blocked angiogenesis induced by VEGF-transfected MCF-7 breast carcinoma cells and the cells remained dormant in the cornea. Postcapillary endothelial cell migration and growth induced by VEGF were blocked by both the NO synthase inhibitor Nomega-mono-methyl--arginine and by the guanylate cyclase inhibitor LY 83583. We conclude that NO is a downstream imperative of VEGF-, but not bFGF-induced angiogenesis, and propose that the NO synthase/guanylate cyclase pathway is a potential target for controlling tumor angiogenesis in response to VEGF. Our studies support recent evidence that VEGF and bFGF induce angiogenesis by different mechanistic pathways using the alphavbeta5 and alphavbeta3 integrins, respectively.

Ziche, M., Morbidelli, L., Chouduri, R., Zhang, H.T., Donnini, S., Granger, H.J., et al. (1997). Nitric oxide synthase lies downstream of vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. THE JOURNAL OF CLINICAL INVESTIGATION, 99(11), 2625-2634 [10.1172/JCI119451].

Nitric oxide synthase lies downstream of vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis

Ziche, Marina;Morbidelli, Lucia;Donnini, Sandra;
1997-01-01

Abstract

Systemic administration of the nitric oxide (NO) synthase inhibitor Nomega-nitro--arginine methyl ester (L-NAME) to rabbits bearing a corneal implant blocked vascular endothelial growth factor (VEGF), but not basic fibroblast growth factor (bFGF)-induced angiogenesis. L-NAME completely blocked angiogenesis induced by VEGF-transfected MCF-7 breast carcinoma cells and the cells remained dormant in the cornea. Postcapillary endothelial cell migration and growth induced by VEGF were blocked by both the NO synthase inhibitor Nomega-mono-methyl--arginine and by the guanylate cyclase inhibitor LY 83583. We conclude that NO is a downstream imperative of VEGF-, but not bFGF-induced angiogenesis, and propose that the NO synthase/guanylate cyclase pathway is a potential target for controlling tumor angiogenesis in response to VEGF. Our studies support recent evidence that VEGF and bFGF induce angiogenesis by different mechanistic pathways using the alphavbeta5 and alphavbeta3 integrins, respectively.
1997
Ziche, M., Morbidelli, L., Chouduri, R., Zhang, H.T., Donnini, S., Granger, H.J., et al. (1997). Nitric oxide synthase lies downstream of vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. THE JOURNAL OF CLINICAL INVESTIGATION, 99(11), 2625-2634 [10.1172/JCI119451].
File in questo prodotto:
File Dimensione Formato  
JClinInvest1997.pdf

non disponibili

Tipologia: Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 590.5 kB
Formato Adobe PDF
590.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/30560
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo